

**Table 1. Relationship between molecules and clinicopathologic features**

	VEGF		B7-H4 (B7.x)		PD-1		PD-L1	
	(pg/ml)	p value	(ng/ml)	p value	(pg/ml)	p value	(pg/ml)	p value
	mean ± S.D		mean ± S.D		mean ± S.D		mean ± S.D	
RCC patients (n=181)	151.0 ± 192.9	<b>0.0028</b>	2.272 ± 3.556	<b>0.00001</b>	18.1 ± 12.2	0.2649	22.5 ± 18.5	<b>0.0218</b>
Healthy volunteers (n=25)	38.1 ± 23.7		0.141 ± .121		14.1 ± 6.3		11.6 ± 5.0	
Karnofsky performance status								
> 80 % (n=140)	89.9 ± 123.5	<b>0.00008</b>	1.402 ± 3.172	<b>0.00003</b>	17.2 ± 11.9	0.2721	17.2 ± 14.6	<b>0.0001</b>
< 80 % (n=41)	292.4 ± 245.9		4.287 ± 3.619		20.0 ± 12.8		34.7 ± 20.9	
Grade								
1 (n=18)	38.4 ± 34.9	<b>0.00007</b>	0.553 ± 0.920	<b>0.00003</b>	15.8 ± 12.2	0.1298	13.2 ± 12.2	<b>0.0004</b>
2 (n=84)	89.5 ± 109.4		1.242 ± 2.659		16.1 ± 11.0		15.8 ± 13.2	
3 (n=68)	261.9 ± 227.5		4.123 ± 4.254		21.8 ± 12.2		33.9 ± 19.2	
4 (n=11)	596.8 ± 146.8		8.122 ± 2.524		17.3 ± 10.3		56.9 ± 16.6	
pT								
1/2 (n=103)	64.5 ± 69.1	<b>0.00007</b>	0.718 ± 1.170	<b>0.00002</b>	13.5 ± 7.4	<b>0.0016</b>	14.2 ± 11.4	<b>0.00008</b>
3/4 (n=78)	233.1 ± 232.6		3.741 ± 4.348		21.6 ± 13.3		30.3 ± 20.5	
pN								
0 (n=168)	122.4 ± 172.6	<b>0.00004</b>	1.836 ± 3.336	<b>0.00009</b>	17.6 ± 11.9	0.7279	20.1 ± 17.1	<b>0.0007</b>
1/2 (n=13)	318.0 ± 221.9		4.825 ± 3.827		18.3 ± 10.1		36.4 ± 21.0	
microscopic vessel invasion (v)								
v (-) (n=78)	54.5 ± 63.9	<b>0.00005</b>	0.675 ± 1.709	<b>0.00007</b>	13.5 ± 8.6	<b>0.0018</b>	11.7 ± 11.1	<b>0.00003</b>
v (+) (n=103)	213.1 ± 222.6		3.301 ± 4.067		21.1 ± 12.4		29.2 ± 19.4	
Metastasis (M)								
M0 (n=118)	105.1 ± 166.2	<b>0.0019</b>	1.492 ± 3.375	<b>0.0003</b>	16.1 ± 10.5	0.1316	17.8 ± 15.9	<b>0.0002</b>
M1 (n=63)	225.2 ± 210.6		3.528 ± 3.529		20.2 ± 12.8		29.9 ± 20.2	
Adjuvant therapy								
Sunitinib (1st line): CR/PR/SD>24w* (n=36)	213.3 ± 139.5	<b>0.0382</b>	1.611 ± 1.878	<b>0.0024</b>	19.7 ± 6.4	0.6531	21.1 ± 3.1	<b>0.0216</b>
Axitinib (2nd line): CR/PR/SD>24w* (n=23)	221.7 ± 168.4		2.062 ± 2.590		21.5 ± 9.5		26.7 ± 18.4	
Axitinib (2nd line): SD<24w/PD* (n=17)	512.4 ± 198.4		6.804 ± 3.707		20.6 ± 10.1		46.8 ± 18.2	

CR/PR/SD>24w\* : complete, partial, or stable with > 24 weeks response

SD<24w/PD\* : stable disease for < 24 weeks or progressive disease